The FDA has approved Newton, PA-based CollaGenex's Oracea, the first orally administered drug for the inflammatory lesions caused by the skin condition rosacea. Roughly 14 million people suffer from rosacea in the U.S. and Oracea will hit the market for them in July.
"Oracea is the first of a series of dermatology products we have in development, and we are very pleased that our NDA was approved by the FDA within 10 months of submission," said CollaGenex CEO Colin Stewart. "Sufficient quantities of Oracea capsules have been manufactured for launch and can now be packaged for distribution to the trade in July. Over the past six months, we have built a first-rate specialty sales force to launch Oracea."
- read the release on Oracea